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Background
Abacavir (ABC), a nucleoside-analogue reverse transcrip-
tase inhibitor, is associated with severe hypersensitivity
reactions that involve the activation of CD8+ T cells in a
HLA-B*57:01-restricted manner. Recent studies have
claimed that non-covalent interactions of ABC with
HLA-B*57:01 are responsible for the immunological
reactions associated with ABC. However, the formation
of haemoglobin-ABC aldehyde (ABCA) adducts in
patients exposed to ABC suggests that protein conjuga-
tion might represent a pathway for antigen formation.
Method
To further characterize protein conjugation reactions,
we used mass spectrometric methods to define ABCA
modifications of human serum albumin and glutathione
S-transferase Pi in vitro and in patients commencing
ABC therapy.
Results
ABCA formed a novel intramolecular cross-linking adduct
on human serum albumin in patients and in vitro via
Michael addition, followed by nucleophilic adduction of
the aldehyde with a neighbouring protein nucleophile.
Adducts were detected on lysine, histidine, and cysteine
residues in subdomain IB of human serum albumin. Only
a cysteine adduct and a putative cross-linking adduct were
detected on glutathione S-transferase Pi. Modelling the
docking of ABCA with HLA B*57:01 confirmed that
ABCA has a strong binding affinity when bound covalently
to Ser116, a key residue with regards to recognition by
ABC-specific CD8+ T cells.
Conclusion
These findings reveal that ABC forms novel types of hap-
tens in all patients taking the drug. It is therefore vital that
the immunological consequences of such haptenation
pathways are explored in the in vitro models that have
been used by various groups to define a new mechanism
of drug hypersensitivity for ABC.
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